ArticleEuropean journal of nuclear medicine and molecular imaging2026
[
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn prostate cancer, Lutetium-177 ([177Lu]Lu )-Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) shows benefit even in earlier stages of the treatment course, potentially leading to broader application also in younger patients. However, evidence regarding its efficacy and safety in this population remains limited.
methodsBased on Gleason score, baseline prostate specific antigen (PSA) and prior chemotherapy status, 51 patients ≤ 65 years of age were matched to 51 patients ≥ 70 years. All patients were scheduled for [177Lu]Lu-PSMA RLT. Efficacy was evaluated using relative PSA changes after two cycles, along with progression-free survival (PFS, defined as time from 1st RLT to ≥ 25% PSA increase from nadir) and overall survival (OS). Safety was assessed by changes in estimated glomerular filtration rate (eGFR), hemoglobin (Hb), white blood cells (WBC) and platelets from baseline to nadir, alongside Common Terminology Criteria of Adverse Events (CTCAE 5.0) grading for chronic kidney disease (CKD), anemia, leukocytopenia and thrombocytopenia.
resultsRLT showed similar efficacy in both age groups with comparable PSA changes after two cycles (younger patients: -8%; Interquartile range [IQR], -55 to 46% versus older subjects: -20%, IQR, -71 to 46%; P = 0.766). No significant differences were observed for PFS (P = 0.882) and OS (P = 0.17). RLT was safe in both age groups, although eGFR, Hb, WBC and platelets declined significantly in both cohorts (P ≤ 0.001 each). Younger patients showed slightly better tolerance, with smaller decreases in Hb (P = 0.021) and platelets (P = 0.013), along with fewer grade 3 events (young vs. old: anemia, 2 vs. 7 and thrombocytopenia, 0 vs. 2).
conclusion[177Lu]Lu-PSMA RLT is a safe and effective treatment option in patients ≤ 65 years old, demonstrating comparable efficacy and a slightly more favorable safety profile relative to older patients. These findings support the use of [177Lu]Lu-PSMA RLT regardless of age, which may be of importance given recent expansion of the indication spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.